Prevail Therapeutics develops AAV-based, disease-modifying gene therapies aiming to address devastating neurodegenerative diseases. The company leverages breakthroughs in human genetics to design its core programs. Proceeds from recent financings will be used to advance its pipeline and grow the team as it transitions into a clinical-stage company. Prevail announced a $50 million Series B and has raised approximately $129 million to date. The company was founded in 2017 through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY. Prevail Therapeutics is developing AAV-based gene therapies that target lysosomal dysfunction to treat genetically-defined neurodegenerative diseases. The company holds an exclusive worldwide license with REGENXBIO to develop and commercialize products using REGENXBIO’s NAV AAV9 vector. Its lead program, PR001, is being developed for a genetic subset of Parkinson’s disease and other mechanistically-related disorders. Prevail plans to build a pipeline addressing additional disease areas where lysosomal dysfunction is an underlying cause. The company was launched in 2017 by the Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed and is headquartered in New York, NY. Prevail announced a $75 million Series A financing to advance its development programs.

Total raised

$125M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2019